BCAT-IN-4 - An Overview
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage numerous intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Main trial aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferer